Featured Research

from universities, journals, and other organizations

TB trial highlights challenges with introducing new vaccine into childhood immunization schedule

Date:
June 22, 2011
Source:
Wellcome Trust
Summary:
A new vaccine to combat tuberculosis is less effective at stimulating an immune response when administered to Gambian infants in combination with the routine immunization schedule, according to new results.

A new vaccine to combat tuberculosis is less effective at stimulating an immune response when administered to Gambian infants in combination with the routine immunisation schedule, according to clinical trial results published June 22 in Science Translational Medicine.

The findings may have important implications for designing the most effective immunisation schedules for children, and also for the design of future clinical trials of the new vaccine.

Standard childhood vaccinations are routinely given as part of a schedule known as the Expanded Program on Immunisation, EPI, which helps to improve vaccine coverage in the population by reducing the number of visits to the clinic required. The schedule includes vaccines for diphtheria, tetanus and whooping cough, as well as the current vaccine for TB, Bacille Calmette-Guιrin (BCG). The aim is to vaccinate children in early infancy, in order to protect them from disease as early as possible.

With 1.8 million people per year killed by TB and more than two billion people worldwide infected with the bacteria that causes the disease, it is clear that BCG offers limited protection and there is an urgent need for more effective vaccines against TB.

MVA85A is a vaccine designed to be given after BCG to boost the body's immune response and improve protection against TB. Originally developed by Dr Helen McShane at the University of Oxford with funding from the Wellcome Trust and the Medical Research Council (MRC), it has already been shown to be safe and capable of eliciting powerful immune responses in clinical trials in adults in the UK, Gambia and South Africa. This is the first trial to evaluate safety of the vaccine in infants.

The purpose of the study was to assess whether MVA85A can stimulate immune responses against the tuberculosis bacteria in infants and whether it could feasibly be given at the same time as other childhood vaccines as part of the EPI.

The randomised trial, funded by the Wellcome Trust, the MRC and the European Commission, involved 214 healthy, 4-month-old infants, who had already received BCG at birth. Children were given either EPI alone, MVA85A alone, or MVA85A in conjunction with EPI.

Overall, MVA85A was deemed to be safe, well tolerated and induced a strong immune response. Importantly, the responses to the standard EPI vaccines were not affected by giving MVA85A at the same time. However, the immune response to MVA85A was lower in infants who received it in conjunction with EPI vaccines compared with those that received the new vaccine alone.

Dr McShane, a Wellcome Trust Senior Clinical Research Fellow at the University of Oxford, explains: "It's reassuring to see that MVA85A does not affect immunity to the other vaccines that are included in the EPI and important to see that it is safe in infants. This study will help us determine the best way to integrate MVA85A into routine infant immunisation schedules in future."

Dr Martin Ota, who led the study at the Medical Research Council (MRC) Unit in The Gambia, welcomes the results: "These important results highlight that we have a real opportunity to make sure that children are protected in the future against tuberculosis by introducing effective and well-timed immunisation programmes. This can only be achieved with robust information gathered from well-conducted clinical trials such as this."

"We don't yet know how the immune response we generate with MVA85A relates to protection from TB and we are currently conducting an efficacy trial of a higher dose of the vaccine in South African BCG-vaccinated infants to assess this. The results of this trial will be available in 2012," added Dr McShane.

The South African efficacy trial of MVA85A is supported by a Wellcome Trust Strategic Translation Award. Supporting research to combat infectious disease is one of the Wellcome Trust's strategic goals.

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, commented: "The EPI has been enormously important in protecting successive generations of children from preventable infections for over twenty years. But a limitation of the programme is that not all vaccines can be easily accommodated within a universal vaccination schedule. It is one of the great challenges in public health to resolve this conundrum so that the fruits of today's vaccine research can be delivered to where they are needed with the efficiency that underpins the success of the EPI."


Story Source:

The above story is based on materials provided by Wellcome Trust. Note: Materials may be edited for content and length.


Cite This Page:

Wellcome Trust. "TB trial highlights challenges with introducing new vaccine into childhood immunization schedule." ScienceDaily. ScienceDaily, 22 June 2011. <www.sciencedaily.com/releases/2011/06/110622145900.htm>.
Wellcome Trust. (2011, June 22). TB trial highlights challenges with introducing new vaccine into childhood immunization schedule. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2011/06/110622145900.htm
Wellcome Trust. "TB trial highlights challenges with introducing new vaccine into childhood immunization schedule." ScienceDaily. www.sciencedaily.com/releases/2011/06/110622145900.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) — Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) — A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) — More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins